## Ann R Falsey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5813669/publications.pdf

Version: 2024-02-01

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Incidence of Respiratory Syncytial Virus Infection Among Hospitalized Adults, 2017–2020. Clinical Infectious Diseases, 2022, 74, 1004-1011.	5.8	61
2	Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and postâ€discharge assessed by Respiratory Intensity and Impact Questionnaire. Influenza and Other Respiratory Viruses, 2022, 16, 79-89.	3.4	16
3	Disease Burden Estimates of Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With Comorbidity: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2022, 226, S17-S21.	4.0	34
4	Cost determinants among adults hospitalized with respiratory syncytial virus in the United States, 2017–2019. Influenza and Other Respiratory Viruses, 2022, 16, 151-158.	3.4	22
5	Aberrant newborn TÂcell and microbiota developmental trajectories predict respiratory compromise during infancy. IScience, 2022, 25, 104007.	4.1	5
6	Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination. Scientific Reports, 2022, 12, 7961.	3.3	7
7	Rates of Medically Attended RSV Among US Adults: A Systematic Review and Meta-analysis. Open Forum Infectious Diseases, 2022, 9, .	0.9	43
8	Burden of respiratory syncytial virus infection in community-dwelling older adults in Europe (RESCEU): an international prospective cohort study. European Respiratory Journal, 2021, 57, 2002688.	6.7	55
9	Temporal Dysbiosis of Infant Nasal Microbiota Relative to Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2021, 223, 1650-1658.	4.0	9
10	Airway Gene Expression Correlates of Respiratory Syncytial Virus Disease Severity and Microbiome Composition in Infants. Journal of Infectious Diseases, 2021, 223, 1639-1649.	4.0	17
11	Airway gene-expression classifiers for respiratory syncytial virus (RSV) disease severity in infants. BMC Medical Genomics, 2021, 14, 57.	1.5	5
12	The effect of air pollution on the transcriptomics of the immune response to respiratory infection. Scientific Reports, $2021$ , $11$ , $19436$ .	3.3	7
13	Diagnosis of Streptococcus pneumoniae infection using circulating antibody secreting cells. PLoS ONE, 2021, 16, e0259644.	2.5	3
14	Perceived Everyday Discrimination and C-Reactive Protein Influence on Cognition of Older Black Adults. Innovation in Aging, 2021, 5, 1040-1040.	0.1	0
15	796. Burden of Healthcare-associated (HA) Respiratory Syncytial Virus (RSV) in Hospitalized Adults. Open Forum Infectious Diseases, 2021, 8, S494-S494.	0.9	1
16	A systems genomics approach uncovers molecular associates of RSV severity. PLoS Computational Biology, 2021, 17, e1009617.	3.2	3
17	Safety and Tolerability of an Ad26.RSV.preF-based Vaccine in a Phase 2b Study in Older Adults. Innovation in Aging, 2021, 5, 1045-1045.	0.1	О
18	Global Disease Burden Estimates of Respiratory Syncytial Virus–Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2020, 222, S577-S583.	4.0	231

#	Article	IF	CITATIONS
19	The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis. Journal of Infectious Diseases, 2020, 222, S563-S569.	4.0	74
20	Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis. Journal of Infectious Diseases, 2020, 222, S570-S576.	4.0	54
21	The impact of influenza vaccination on the COVID-19 pandemic? Evidence and lessons for public health policies. Vaccine, 2020, 38, 6485-6486.	3.8	31
22	Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. New England Journal of Medicine, 2020, 383, 2439-2450.	27.0	2,107
23	Unbiased analysis of peripheral blood mononuclear cells reveals CD4 T cell response to RSV matrix protein. Vaccine: X, 2020, 5, 100065.	2.1	0
24	Syncope, Near Syncope, or Nonmechanical Falls as a Presenting Feature of COVID-19. Annals of Emergency Medicine, 2020, 76, 115-117.	0.6	22
25	Respiratory Syncytial Virus: An Old Foe in a New Era. Journal of Infectious Diseases, 2020, 222, 1245-1246.	4.0	3
26	Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. The Cochrane Library, 2019, 2019, CD007498.	2.8	320
27	Respiratory syncytial virus–associated illness in adults with advanced chronic obstructive pulmonary disease and/or congestive heart failure. Journal of Medical Virology, 2019, 91, 65-71.	5.0	43
28	Measuring the Severity of Respiratory Illness in the First 2ÂYears of Life in Preterm and Term Infants. Journal of Pediatrics, 2019, 214, 12-19.e3.	1.8	3
29	Microbiome-Transcriptome Interactions Related to Severity of Respiratory Syncytial Virus Infection. Scientific Reports, 2019, 9, 13824.	3.3	30
30	What is the role of rapid molecular testing for seniors and other at-risk adults with respiratory syncytial virus infections?. Journal of Clinical Virology, 2019, 117, 27-32.	3.1	5
31	Highly efficient hypothesis testing methods for regression-type tests with correlated observations and heterogeneous variance structure. BMC Bioinformatics, 2019, 20, 185.	2.6	3
32	Viral pathogens associated with acute respiratory illness in hospitalized adults and elderly from Zagreb, Croatia, 2016 to 2018. Journal of Medical Virology, 2019, 91, 1202-1209.	5.0	16
33	2315. The Relationship of Pre-Hospital Functional Status and Clinical Outcomes in Patients with Laboratory-Confirmed RSV Infection: Active Population-Based Surveillance, 2017–2019. Open Forum Infectious Diseases, 2019, 6, S794-S794.	0.9	0
34	415. Airway Gene-Expression Classifiers for Respiratory Syncytial Virus (RSV) Disease Severity in Infants. Open Forum Infectious Diseases, 2019, 6, S210-S210.	0.9	0
35	2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate. Open Forum Infectious Diseases, 2019, 6, S970-S970.	0.9	5
36	92. Incidence of Respiratory Syncytial Virus Infection among Hospitalized Adults, 2017–2019. Open Forum Infectious Diseases, 2019, 6, S7-S8.	0.9	1

#	Article	IF	CITATIONS
37	Host Gene Expression in Nose and Blood for the Diagnosis of Viral Respiratory Infection. Journal of Infectious Diseases, 2019, 219, 1151-1161.	4.0	43
38	Aims, Study Design, and Enrollment Results From the Assessing Predictors of Infant Respiratory Syncytial Virus Effects and Severity Study. JMIR Research Protocols, 2019, 8, e12907.	1.0	9
39	Influenza burden in frail elderly. Lancet Respiratory Medicine,the, 2018, 6, e2.	10.7	5
40	Virus-Specific Antibody, Viral Load, and Disease Severity in Respiratory Syncytial Virus Infection. Journal of Infectious Diseases, 2018, 218, 208-217.	4.0	34
41	Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 95-107.	9.1	337
42	733. Incidence and Evaluation of the Change in Functional Status Associated with Respiratory Syncytial Virus Infection in Hospitalized Older Adults. Open Forum Infectious Diseases, 2018, 5, S263-S263.	0.9	3
43	Neonatal gut and respiratory microbiota: coordinated development through time and space. Microbiome, 2018, 6, 193.	11.1	68
44	Effect of prior vaccination on carriage rates of Streptococcus pneumoniae in older adults: A longitudinal surveillance study. Vaccine, 2018, 36, 4304-4310.	3.8	21
45	The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. Lancet Infectious Diseases, The, 2018, 18, e295-e311.	9.1	355
46	Development of a Global Respiratory Severity Score (GRSS) for Respiratory Syncytial Virus Infection in Infants. Journal of Infectious Diseases, 2017, 215, jiw624.	4.0	32
47	An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults. Journal of Infectious Diseases, 2017, 216, 1362-1370.	4.0	88
48	Viral Diagnostics: Only Half the Battle. Journal of Infectious Diseases, 2017, 216, 923-925.	4.0	8
49	Can Analysis of Routine Viral Testing Provide Accurate Estimates of Respiratory Syncytial Virus Disease Burden in Adults?. Journal of Infectious Diseases, 2017, 215, 1706-1710.	4.0	19
50	Association of Dynamic Changes in the CD4 T-Cell Transcriptome With Disease Severity During Primary Respiratory Syncytial Virus Infection in Young Infants. Journal of Infectious Diseases, 2017, 216, 1027-1037.	4.0	17
51	Transcriptomic Biomarkers to Discriminate Bacterial from Nonbacterial Infection in Adults Hospitalized with Respiratory Illness. Scientific Reports, 2017, 7, 6548.	3.3	54
52	Management of Respiratory Infections with Use of Procalcitonin: Moving toward More Personalized Antibiotic Treatment Decisions. ACS Infectious Diseases, 2017, 3, 875-879.	3.8	13
53	Pseudomonas Endocarditis with an unstable phenotype: the challenges of isolate characterization and Carbapenem stewardship with a partial review of the literature. Antimicrobial Resistance and Infection Control, 2017, 6, 87.	4.1	2
54	Compassionate Use Experience with High Titer RSV Immunoglobulin (RSV-IVIG) in RSV Infected Immunocompromised Persons. Open Forum Infectious Diseases, 2016, 3, .	0.9	0

#	Article	IF	CITATIONS
55	Provider Decisions to Treat Respiratory Illnesses with Antibiotics: Insights from a Randomized Controlled Trial. PLoS ONE, 2016, 11, e0152986.	2.5	19
56	LytA-Positive Streptococcus mitis/oralis Confound Interpretation of Pneumococcal Colonization Studies. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
57	Immunogenicity of AS03-adjuvanted and non-adjuvanted trivalent inactivated influenza vaccines in elderly adults: A Phase 3, randomized trial and $\langle i \rangle$ post-hoc $\langle i \rangle$ correlate of protection analysis. Human Vaccines and Immunotherapeutics, 2016, 12, 3043-3055.	3.3	5
58	Parainfluenza Virus Infection. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 538-554.	2.1	140
59	Challenges and opportunities in RSV vaccine development: Meeting report from FDA/NIH workshop. Vaccine, 2016, 34, 4843-4849.	3.8	49
60	The Healthy Infant Nasal Transcriptome: A Benchmark Study. Scientific Reports, 2016, 6, 33994.	3.3	25
61	Development of Electrochemiluminescent Serology Assays to Measure the Humoral Response to Antigens of Respiratory Syncytial Virus. PLoS ONE, 2016, 11, e0153019.	2.5	14
62	Should clinical case definitions of influenza in hospitalized older adults include fever?. Influenza and Other Respiratory Viruses, 2015, 9, 23-29.	3.4	53
63	Therapeutic Immunoglobulin Selected for High Antibody Titer to RSV also Contains High Antibody Titers to Other Respiratory Viruses. Frontiers in Immunology, 2015, 6, 431.	4.8	27
64	Safety and immunogenicity of a quadrivalent intradermal influenza vaccine in adults. Vaccine, 2015, 33, 1151-1159.	3.8	32
65	Serum Procalcitonin Measurement and Viral Testing to Guide Antibiotic Use for Respiratory Infections in Hospitalized Adults: A Randomized Controlled Trial. Journal of Infectious Diseases, 2015, 212, 1692-1700.	4.0	103
66	Respiratory Syncytial Virus Infection in Older Adults: An Under-Recognized Problem. Drugs and Aging, 2015, 32, 261-269.	2.7	123
67	Diversifying Selection Analysis Predicts Antigenic Evolution of 2009 Pandemic H1N1 Influenza A Virus in Humans. Journal of Virology, 2015, 89, 5427-5440.	3.4	21
68	Superiority of Transcriptional Profiling Over Procalcitonin for Distinguishing Bacterial From Viral Lower Respiratory Tract Infections in Hospitalized Adults. Journal of Infectious Diseases, 2015, 212, 213-222.	4.0	146
69	Respiratory Syncytial Virus and Other Respiratory Viral Infections in Older Adults With Moderate to Severe Influenza-like Illness. Journal of Infectious Diseases, 2014, 209, 1873-1881.	4.0	206
70	Reply to Musher et al. Journal of Infectious Diseases, 2014, 209, 633-635.	4.0	0
71	Detection of Respiratory Viruses in Sputum from Adults by Use of Automated Multiplex PCR. Journal of Clinical Microbiology, 2014, 52, 3590-3596.	3.9	64
72	Risk Factors for Respiratory Syncytial Virus Illness Among Patients with Chronic Obstructive Pulmonary Disease. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 293-299.	1.6	48

#	Article	IF	Citations
73	Bacterial Complications of Respiratory Tract Viral Illness: A Comprehensive Evaluation. Journal of Infectious Diseases, 2013, 208, 432-441.	4.0	127
74	Clinical Impact of Human Coronaviruses 229E and OC43 Infection in Diverse Adult Populations. Journal of Infectious Diseases, 2013, 208, 1634-1642.	4.0	145
75	Consequences of Immature and Senescent Immune Responses for Infection with Respiratory Syncytial Virus. Current Topics in Microbiology and Immunology, 2013, 372, 211-231.	1.1	35
76	Viral Shedding and Immune Responses to Respiratory Syncytial Virus Infection in Older Adults. Journal of Infectious Diseases, 2013, 207, 1424-1432.	4.0	110
77	Respiratory Syncytial Virus Infection in Adult Populations. Infectious Disorders - Drug Targets, 2012, 12, 98-102.	0.8	101
78	Yield of Sputum for Viral Detection by Reverse Transcriptase PCR in Adults Hospitalized with Respiratory Illness. Journal of Clinical Microbiology, 2012, 50, 21-24.	3.9	57
79	Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. International Journal of COPD, 2012, 7, 127.	2.3	39
80	Current management of parainfluenza pneumonitis in immunocompromised patients: a review. Infection and Drug Resistance, 2012, 5, 121.	2.7	35
81	The Effect of Steroid Use in Hospitalized Adults With Respiratory Syncytial Virus-Related Illness. Chest, 2011, 140, 1155-1161.	0.8	45
82	The Diagnosis of Viral Respiratory Disease in Older Adults. Clinical Infectious Diseases, 2010, 50, 100201102709029-000.	5.8	111
83	Humoral immunity to human metapneumovirus infection in adults. Vaccine, 2010, 28, 1477-1480.	3.8	36
84	New emerging technologies and the intradermal route: the novel way to immunize against influenza. Vaccine, 2010, 28, D24-D32.	3.8	11
85	Randomized, Doubleâ€Blind Controlled Phase 3 Trial Comparing the Immunogenicity of Highâ€Dose and Standardâ€Dose Influenza Vaccine in Adults 65 Years of Age and Older. Journal of Infectious Diseases, 2009, 200, 172-180.	4.0	334
86	Risk Factors for Respiratory Failure Associated with Respiratory Syncytial Virus Infection in Adults. Journal of Infectious Diseases, 2009, 200, 1242-1246.	4.0	73
87	Microneutralization assay for the measurement of neutralizing antibodies to human metapneumovirus. Journal of Clinical Virology, 2009, 46, 314-317.	3.1	15
88	Detection of genetic lineages of human metapneumovirus in Croatia during the winter season 2005/2006. Journal of Medical Virology, 2008, 80, 1282-1287.	5.0	17
89	Longâ€Term Care Facilities: A Cornucopia of Viral Pathogens. Journal of the American Geriatrics Society, 2008, 56, 1281-1285.	2.6	53
90	Comparison of the Safety and Immunogenicity of 2 Respiratory Syncytial Virus (RSV) Vaccines— Nonadjuvanted Vaccine or Vaccine Adjuvanted with Alum—Given Concomitantly with Influenza Vaccine to Highâ€Risk Elderly Individuals. Journal of Infectious Diseases, 2008, 198, 1317-1326.	4.0	83

#	Article	IF	Citations
91	Human Metapneumovirus Infection in Adults. Pediatric Infectious Disease Journal, 2008, 27, S80-S83.	2.0	55
92	Respiratory Syncytial Virus Infection in Adults. Seminars in Respiratory and Critical Care Medicine, 2007, 28, 171-181.	2.1	138
93	Respiratory Syncytial Virus Infection in Adults. Antiviral Therapy, 2007, 12, 659-670.	1.0	40
94	Detection of respiratory syncytial virus and human metapneumovirus by reverse transcription polymerase chain reaction in adults with and without respiratory illness. Journal of Clinical Virology, 2006, 35, 46-50.	3.1	102
95	Serum antibody decay in adults following natural respiratory syncytial virus infection. Journal of Medical Virology, 2006, 78, 1493-1497.	<b>5.</b> 0	95
96	Detection of Respiratory Syncytial Virus in Adults with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 639-643.	5.6	121
97	Viral Pneumonia in Older Adults. Clinical Infectious Diseases, 2006, 42, 518-524.	5.8	189
98	Respiratory Syncytial Virus Infection in Elderly and High-Risk Adults. New England Journal of Medicine, 2005, 352, 1749-1759.	27.0	1,668
99	Respiratory Syncytial Virus Infection in Elderly Adults. Drugs and Aging, 2005, 22, 577-587.	2.7	159
100	Humoral and Mucosal Immunity in Protection from Natural Respiratory Syncytial Virus Infection in Adults. Journal of Infectious Diseases, 2004, 190, 373-378.	4.0	163
101	Risk Factors for Severe Respiratory Syncytial Virus Infection in Elderly Persons. Journal of Infectious Diseases, 2004, 189, 233-238.	4.0	183
102	Experimental infection of humans with A2 respiratory syncytial virus1. Antiviral Research, 2004, 63, 191-196.	4.1	86
103	Novel coronavirus and severe acute respiratory syndrome. Lancet, The, 2003, 361, 1312-1313.	13.7	61
104	Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. Journal of Clinical Virology, 2003, 28, 169-174.	3.1	141
105	Human Metapneumovirus Infections in Young and Elderly Adults. Journal of Infectious Diseases, 2003, 187, 785-790.	4.0	504
106	Comparison of Quantitative Reverse Transcription-PCR to Viral Culture for Assessment of Respiratory Syncytial Virus Shedding. Journal of Clinical Microbiology, 2003, 41, 4160-4165.	3.9	112
107	Rhinovirus and Coronavirus Infection–Associated Hospitalizations among Older Adults. Journal of Infectious Diseases, 2002, 185, 1338-1341.	4.0	184
108	Diagnosis of Respiratory Syncytial Virus Infection: Comparison of Reverse Transcription-PCR to Viral Culture and Serology in Adults with Respiratory Illness. Journal of Clinical Microbiology, 2002, 40, 817-820.	3.9	153

#	Article	IF	CITATIONS
109	Reverse transcription polymerase chain reaction (RT-PCR) for diagnosis of respiratory syncytial virus infection in adults: Use of a single-tube ?hanging droplet? nested PCR. Journal of Medical Virology, 2001, 63, 259-263.	5.0	50
110	Hepatitis B immunization of healthy elderly adults: relationship between na $\tilde{A}^-$ ve CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. Journal of Clinical Immunology, 2001, 21, 30-36.	3.8	59
111	Comparison of respiratory syncytial virus humoral immunity and response to infection in young and elderly adults., 1999, 59, 221-226.		45
112	Evaluation of a Handwashing Intervention to Reduce Respiratory Illness Rates in Senior Day-Care Centers. Infection Control and Hospital Epidemiology, 1999, 20, 200-202.	1.8	70
113	The "Common Cold―in Frail Older Persons: Impact of Rhinovirus and Coronavirus in a Senior Daycare Center. Journal of the American Geriatrics Society, 1997, 45, 706-711.	2.6	82
114	Evaluation of Four Methods for the Diagnosis of Respiratory Syncytial Virus Infection in Older Adults. Journal of the American Geriatrics Society, 1996, 44, 71-73.	2.6	64
115	Acute Respiratory Tract Infection in Daycare Centers for Older Persons. Journal of the American Geriatrics Society, 1995, 43, 30-36.	2.6	107
116	Respiratory Syncytial Virus and Influenza A Infections in the Hospitalized Elderly. Journal of Infectious Diseases, 1995, 172, 389-394.	4.0	358
117	Humoral immunity to respiratory syncytial virus infection in the elderly. Journal of Medical Virology, 1992, 36, 39-43.	5.0	44